Clinical Trials | December 21, 2025
Takeda posts strong Phase 3 win for oral psoriasis drug
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
This marks the first partnership between Pfizer and Cipla in India
The update promises to revolutionize laboratory workflows by optimizing resources
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
